---
title: "Hangzhou transacted 4.249 billion yuan for 3 residential land plots, with the highest premium rate of 51.38%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/240949782.md"
description: "On May 20th, Hangzhou transacted 3 residential land plots, all located in the core area of the main city, with premium rates exceeding 25%, totaling approximately 4.249 billion yuan. Among them, the Xihu Sandun unit plot was won by POLY PROPERTY for 1.709 billion yuan, with a premium rate of 51.38%; the Gongshu Dongxin unit plot was won by Hangzhou Xifang for 1.625 billion yuan, with a premium rate of 41.93%; the Binjiang Changhe unit plot was won by the Zhongtian and Haiwei consortium for 916 million yuan, with a premium rate of 25.32%"
datetime: "2025-05-20T04:09:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240949782.md)
  - [en](https://longbridge.com/en/news/240949782.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240949782.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/240949782.md) | [English](https://longbridge.com/en/news/240949782.md)


# Hangzhou transacted 4.249 billion yuan for 3 residential land plots, with the highest premium rate of 51.38%

On May 20th, Hangzhou completed three transactions involving residential land, all located in the core area of the main city, with premium rates exceeding 25%, totaling approximately 4.249 billion yuan. Among them, the West Lake Sandun unit plot was won by POLY PROPERTY for 1.709 billion yuan, with a premium rate of 51.38%; the Gongshu Dongxin unit plot was won by Hangzhou Xifang for 1.625 billion yuan, with a premium rate of 41.93%; the Binjiang Changhe unit plot was won by the Zhongtian and Haiwei consortium for 916 million yuan, with a premium rate of 25.32%

### 相關股票

- [POLY PROPERTY (00119.HK)](https://longbridge.com/zh-HK/quote/00119.HK.md)

## 相關資訊與研究

- [Zhongtai Securities Sticks to Its Buy Rating for Wasion Holdings Limited (3393)](https://longbridge.com/zh-HK/news/281141455.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-HK/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [CICC Sticks to Its Buy Rating for CIMC Enric Holdings (CIMEF)](https://longbridge.com/zh-HK/news/281132485.md)
- [Guotai Haitong Remains a Buy on Jinxin Fertility Group Ltd. (1951)](https://longbridge.com/zh-HK/news/281098586.md)